TPDB

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB41078

Peptide_Name

Temporin-PKE-4K

Activity

Anticancer

Activity_category_statistics

Cancer-related peptides

Database_Source

CancerPPD 2.0

Sequence_Type

standard

Has_Modification No

Description A 17-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0, with an available 3D structural model.

Modification

C-terminal: Amidation

Sequence

FLPKIIGKLSSKLPKIF-NH2

FASTA

>TPDB41078|Anticancer|length=17
FLPKIIGKLSSKLPKIF-NH2

Formula C96H161N21O20

Absent Amino Acids ARNDCEQHMTWYV

Common Amino Acids K

Mass 1929.46

PI 11.00

Basic Residues 4

Acidic Residues 0

Hydrophobic Residues 8

Net Charge +4

Boman Index 0.26

Hydrophobicity 0.571

Aliphatic Index 137.65

Half Life

Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min

Extinction Coefficient Cystines 0

Absorbance 280nm 0.00

Polar Residues 2

number

0

A

0

R

0

N

0

D

0

C

0

E

0

Q

1

G

0

H

3

I

3

L

4

K

0

M

2

F

2

P

2

S

0

T

0

W

0

Y

0

V

Amino Acid Distribution

A: 0 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 1 H: 0 I: 3 L: 3 K: 4 M: 0 F: 2 P: 2 S: 2 T: 0 W: 0 Y: 0 V: 0

Length

17

Formula

C96H161N21O20

Mass

1929.46

PI

11.00

Net Charge

+4

Boman Index

0.26

Hydrophobicity

0.571

C_terminal_Modification

Amidation

Chirality

L

Linear_or_Cyclic

Linear

N_terminal_Modification

Free

Nature

Antimicrobial

Origin

Synthetic

Evidence 1 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 85.52 µM

Detail Source Activity Anticancer

Activity Measurement 85.52 µM

Target

Cancer Type Brain Tumor

Cell Line U251-MG

Tissue Affected Brain

Assay & Model

Assay MTT assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2022

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 2 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 49.50 µM

Detail Source Activity Anticancer

Activity Measurement 49.50 µM

Target

Cancer Type Prostate Cancer

Cell Line PC-3

Tissue Affected Prostate

Assay & Model

Assay MTT assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2022

Evidence 3 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 35.28 µM

Detail Source Activity Anticancer

Activity Measurement 35.28 µM

Target

Cancer Type Lung Cancer

Cell Line H-838

Tissue Affected Lung

Assay & Model

Assay MTT assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2022

Evidence 4 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 99.36 µM

Detail Source Activity Anticancer

Activity Measurement 99.36 µM

Target

Cancer Type Colorectal Cancer

Cell Line HCT-116

Tissue Affected Colon

Assay & Model

Assay MTT assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2022

Evidence 5 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 27.76 µM

Detail Source Activity Anticancer

Activity Measurement 27.76 µM

Target

Cancer Type Lung Cancer

Cell Line H-157

Tissue Affected Lung

Assay & Model

Assay MTT assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2022